J.Safra Asset Management Corp Purchases 169 Shares of IQVIA Holdings Inc. $IQV

J.Safra Asset Management Corp raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 208.6% in the second quarter, HoldingsChannel reports. The firm owned 250 shares of the medical research company’s stock after buying an additional 169 shares during the quarter. J.Safra Asset Management Corp’s holdings in IQVIA were worth $39,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC lifted its position in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA during the 1st quarter valued at about $33,000. Trust Co. of Toledo NA OH purchased a new position in shares of IQVIA during the 2nd quarter valued at about $39,000. Finally, Larson Financial Group LLC lifted its position in shares of IQVIA by 109.9% during the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after buying an additional 144 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on IQV shares. Truist Financial lifted their price objective on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. UBS Group lifted their price objective on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Finally, HSBC raised IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Stock Up 0.5%

NYSE IQV opened at $204.76 on Wednesday. The stock’s 50 day moving average is $189.86 and its 200 day moving average is $168.55. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $237.34. The stock has a market cap of $34.81 billion, a PE ratio of 29.63, a P/E/G ratio of 2.24 and a beta of 1.32.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.